The Program of Applied Translational Research (PATR) is dedicated to the process of applying discoveries generated in the laboratory and in preclinical experiments, to the development of clinical studies, and to the design of clinical trials. As a critical component of this mission, the Program also seeks to conduct translational research to advance the mechanistic understanding of novel biomarkers to enhance their clinical utility in complex diseases. Our multidisciplinary team is comprised of talented physicians and scientists committed to patient-oriented research and developing solutions in clinical medicine and disease management in the community. The Program aims to combine the creativity, commitment, experience, and skills of our physician-scientists to improve the care of our patients.
The creation of the PATR in 2012 was preceded by the formation of the Translational Research Investigating Biomarker End-Points (TRIBE) consortium in 2005. This multidisciplinary consortium was formed to assist in the efficient development and validation of novel biomarkers of acute kidney injury (AKI). The TRIBE consortium, which is now an integral part of PATR, has proven expertise in developing assays for several of the AKI biomarkers, as well as broad expertise required for general biomarker development.
The Program develops novel translational research methodologies for assessing biomarker performance and identifies innovative strategies to treat complex clinical disorders, such as peri-operative kidney injury, post-transplantation kidney injury, and hepatorenal and cardiorenal syndromes. A large biosample repository with associated bioinformatics has been established to support all phases of translational research and biomarker development. The Program also recruits and trains students and young scientists in translational research education.
We have created a collaborative environment and actively seek the perspective of those who will use or potentially benefit from our research. Our ultimate goal is to demonstrate that patients directly benefit from the applied science we develop.